Donaldson Capital Management LLC trimmed its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 30.9% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 41,818 shares of the company's stock after selling 18,715 shares during the period. Donaldson Capital Management LLC's holdings in Johnson & Johnson were worth $6,935,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other institutional investors have also modified their holdings of the company. WealthTrak Capital Management LLC purchased a new position in shares of Johnson & Johnson in the 4th quarter valued at approximately $26,000. Mountain Hill Investment Partners Corp. acquired a new stake in shares of Johnson & Johnson during the 4th quarter worth approximately $29,000. Conquis Financial LLC acquired a new position in shares of Johnson & Johnson in the 4th quarter valued at $33,000. Bernard Wealth Management Corp. acquired a new position in shares of Johnson & Johnson in the 4th quarter valued at $36,000. Finally, Runnymede Capital Advisors Inc. acquired a new position in shares of Johnson & Johnson in the 4th quarter valued at $38,000. 69.55% of the stock is currently owned by institutional investors.
Wall Street Analysts Forecast Growth
A number of equities research analysts recently issued reports on JNJ shares. Sanford C. Bernstein reissued a "market perform" rating on shares of Johnson & Johnson in a research note on Wednesday, April 16th. Guggenheim reiterated a "neutral" rating on shares of Johnson & Johnson in a report on Wednesday, April 2nd. Leerink Partnrs lowered shares of Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a report on Tuesday, May 13th. Royal Bank of Canada reiterated an "outperform" rating and set a $181.00 target price on shares of Johnson & Johnson in a report on Thursday, June 5th. Finally, The Goldman Sachs Group raised Johnson & Johnson from a "neutral" rating to a "buy" rating and boosted their price objective for the stock from $157.00 to $172.00 in a research report on Wednesday, April 9th. Eleven analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $170.88.
Read Our Latest Analysis on Johnson & Johnson
Johnson & Johnson Stock Performance
NYSE:JNJ traded up $1.35 during trading hours on Thursday, reaching $156.61. 7,065,256 shares of the company's stock were exchanged, compared to its average volume of 7,948,711. The firm has a market capitalization of $376.82 billion, a price-to-earnings ratio of 23.55, a P/E/G ratio of 2.56 and a beta of 0.42. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $169.99. The company has a 50-day moving average of $153.56 and a 200 day moving average of $153.70.
Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.59 by $0.18. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The business had revenue of $21.89 billion during the quarter, compared to the consensus estimate of $21.65 billion. Research analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current year.
Johnson & Johnson Increases Dividend
The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th were issued a dividend of $1.30 per share. This is a boost from Johnson & Johnson's previous quarterly dividend of $1.24. The ex-dividend date of this dividend was Tuesday, May 27th. This represents a $5.20 annualized dividend and a dividend yield of 3.32%. Johnson & Johnson's dividend payout ratio (DPR) is 57.84%.
Johnson & Johnson Company Profile
(
Free Report)
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
Featured Articles
Before you consider Johnson & Johnson, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.
While Johnson & Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
